iCAD Inc  

(Public, NASDAQ:ICAD)   Watch this stock  
Find more results for ICAD
+0.10 (3.12%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.10 - 3.43
52 week 2.93 - 6.07
Open 3.17
Vol / Avg. 0.00/37,796.00
Mkt cap 54.26M
P/E     -
Div/yield     -
EPS -0.82
Shares 16.44M
Beta 1.44
Inst. own 30%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -99.04% -38.34%
Operating margin -99.17% -37.85%
EBITD margin - -30.05%
Return on average assets -77.71% -23.14%
Return on average equity -131.09% -34.95%
Employees 116 -
CDP Score - -


98 Spit Brook Rd Ste 100
NASHUA, NH 03062-5737
United States - Map
+1-603-8825200 (Phone)
+1-603-8803843 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.

Officers and directors

Lawrence Howard Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Kenneth M. Ferry Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard C. Christopher Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Stacey M. Stevens Senior Vice President - Marketing and Strategy
Age: 48
Bio & Compensation  - Reuters
Jonathan Go Senior Vice President - Research and Development
Age: 52
Bio & Compensation  - Reuters
R. Scott Areglado Vice President, Corporate Controller
Bio & Compensation  - Reuters
Andrew Heroux Sassine Director
Age: 52
Bio & Compensation  - Reuters
Rachel Brem M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Anthony F. Ecock Independent Director
Age: 53
Bio & Compensation  - Reuters
Robert L. Goodman M.D. Independent Director
Age: 74
Bio & Compensation  - Reuters